VolitionRX (VNRX) Q4 2024 earnings summary

Executive summary

• Achieved significant clinical and commercial milestones in 2024, including expansion of the Nu.Q Vet Cancer Test to over 20 countries and sales of approximately 120,000 tests.

• Completed multiple independent studies validating the Nu.Q platform in sepsis and oncology.

• Advanced commercial discussions for licensing and supply agreements in human diagnostics and liquid biopsy markets.

• Strengthened board with appointments of Timothy Still as chair and Dr. Ethel Rubin as independent director.

• 2025 priorities include signing multiple human licensing deals and further commercialization in both animal and human health.

Financial highlights

• 2024 revenue reached $1.2 million, up 59% year-over-year; Nu.Q Vet revenue grew 75% and Nu.Q Discover revenue increased 40%.

• Operating expenses decreased 23% year-over-year, with H2 2024 down 31% from prior year.

• Cash and equivalents at year-end were $3.3 million.

• Received $1.8 million in non-dilutive funding in 2024 and similar amounts post year-end, plus $2.3 million from equity sales.

• First revenue from Nu.Q NETs recorded in 2024.

Outlook and guidance

• Targeting cash neutrality in 2025, driven by licensing receipts and continued cost control.

• 2025 focus is on signing multiple licensing deals for human indications, with strong commercial interest.

• No specific revenue guidance for 2025 due to early commercialization stage and revenue lumpiness.

• Anticipates publication of numerous studies in 2025 to support commercial efforts.

• Expecting significant revenue growth from automation in centralized labs and larger licensing deals.